Valuation: ARS Pharmaceuticals, Inc.

Market Cap 39Cr 35Cr 32Cr 29Cr 55Cr 3.71TCr 56Cr 388.09Cr 153.51Cr 1.94TCr 146.31Cr 143.19Cr 6.14TCr P/E 2026 *
-2.11x
P/E 2027 * -4.64x
Enterprise Value 39Cr 35Cr 32Cr 29Cr 55Cr 3.71TCr 56Cr 388.09Cr 153.51Cr 1.94TCr 146.31Cr 143.19Cr 6.14TCr EV / Sales 2026 *
3.03x
EV / Sales 2027 * 2.08x
Free-Float
83.82%
Yield 2026 *
-
Yield 2027 * -
1 day-2.73%
1 week-7.33%
Current month-9.05%
1 month-3.92%
3 months-34.01%
6 months-52.71%
Current year-66.35%
1 week 3.9
Extreme 3.9
4.42
1 month 3.81
Extreme 3.8101
4.64
Current year 3.81
Extreme 3.8101
13.15
1 year 3.81
Extreme 3.8101
13.15
3 years 3.38
Extreme 3.38
18.9
5 years 2.55
Extreme 2.55
18.9
10 years 2.55
Extreme 2.55
18.9
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 05/08/2015
Chief Executive Officer 53 07/07/2026
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 56 08/11/2022
Director/Board Member 55 01/08/2021
Director/Board Member 56 01/07/2017
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Chief Executive Officer

10,36,923 1.0427%
01/09/26 Free

Executive/Senior Manager

10,01,738 1.0073%
01/07/26 Free

Chief Executive Officer

8,98,456 0.9048%
Change 5-day change 1-year change 3-year change Capi.($)
-2.73%-7.33%-56.97%+11.36% 40Cr
+0.88%-0.34%+40.64%+73.05% 6.47TCr
-0.26%+6.91%+11.14%+77.36% 5.48TCr
+0.47%+3.52%+8.22%+100.95% 5.35TCr
-2.06%+2.90%+24.07%+48.36% 4.6TCr
-1.79%+0.19%+19.32%+123.62% 4.29TCr
-1.65%+0.96%+237.56%+823.66% 4.01TCr
-2.26%-4.14%+15.38%+45.53% 3.35TCr
-2.96%-11.01%+19.47%-6.72% 2.4TCr
+12.10%+16.60%+55.14%+46.15% 2.37TCr
Average -0.03%+0.41%+37.40%+134.33% 3.84TCr
Weighted average by Cap. -0.08%+1.61%+45.37%+149.58%

Financials

2026 *2027 *
Net sales 13Cr 11Cr 11Cr 9.63Cr 18Cr 1.22TCr 18Cr 128.01Cr 51Cr 639.84Cr 48Cr 47Cr 2.03TCr 19Cr 17Cr 15Cr 14Cr 26Cr 1.78TCr 27Cr 186.27Cr 74Cr 931.1Cr 70Cr 69Cr 2.95TCr
Net income -18Cr -17Cr -15Cr -14Cr -26Cr -1.76TCr -26Cr -184.08Cr -73Cr -920.15Cr -69Cr -68Cr -2.91TCr -8.52Cr -7.62Cr -7.05Cr -6.38Cr -12Cr -810.29Cr -12Cr -85Cr -34Cr -423.81Cr -32Cr -31Cr -1.34TCr
Net Debt - -
Projected Income Statement - Annual - ARS Pharmaceuticals, Inc.
Logo ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
Employees
198
Date Price Change Volume
26/26/26 $3.920 -2.73% 14,33,831
23/26/23 $4.030 -6.71% 15,22,195
22/26/22 $4.320 +3.35% 17,87,746
21/26/21 $4.180 -2.56% 10,10,610
20/26/20 $4.290 +1.42% 15,42,751
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - ARS Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.920USD
Average target price
24.33USD
Spread / Average Target
+520.75%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ARS Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. SPRY Stock